tbrady@bio.org
Washington, D.C. – As the Biotechnology Innovation Organization (BIO) continues to restructure for a stronger and reinvigorated future, the organization announced new leadership for operations and sustainability.
Shaye Mandle was named Chief Operating Officer (COO), effective March 1, 2021.
Shaye Mandle
With extensive experience in restructuring and rebranding organizations and coming from Minnesota’s Medical Alley Association, Mandle will work to position BIO for the future with aggressive plans to forge enduring partnerships with state organizations, monitor and strengthen internal processes to coincide with BIO’s mission, and reinvigorate BIO’s premier in-person events when it is safe to have them again.
Press release content from Accesswire. The AP news staff was not involved in its creation.
BIO-Europe Spring Connects the Right Partners at Europe’s Largest Springtime Digital Life Science Partnering Event
February 15, 2021 GMT
MUNICH, GERMANY / ACCESSWIRE / February 15, 2021 / The fifteenth annual BIO-Europe Spring (R) conference, the premier springtime partnering conference for the life science industry, again is delivered fully digital for its 2021 edition. With an expanded format to four 24-hour days the event will accommodate partnering meetings between attendees from all over the world. BIO-Europe Spring is produced by EBD Group, the leading partnering firm for the global life science industry, with the support of the Biotechnology Innovation Organization (BIO).
Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer Cindy Collins to Step Down Effective February 15, 2021
February 08, 2021 08:00 ET | Source: Editas Medicine, Inc. Editas Medicine, Inc. Cambridge, Massachusetts, UNITED STATES
CAMBRIDGE, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that James (Jim) C. Mullen will succeed Cynthia (Cindy) Collins as Chief Executive Officer, effective February 15, 2021. Mr. Mullen will continue as Chairman of the Company’s Board of Directors.
“On behalf of the entire Board, I thank Cindy for her tremendous contributions and dedication to Editas Medicine,” said James C. Mullen, Chairman, Editas Medicine. “Under Cindy’s leadership, the Company initiated the EDIT-101 clinical trial – the first ever administration of an
Development and distribution of the COVID-19 vaccine has been a massive undertaking. An “all hands on deck” approach has led to a vaccine emergency approval faster than expected. Now a similar approach must be taken in regards to getting the vaccine into the arms of Americans.
The vaccine development and rollout were the topics of discussion for the House Health Policy Committee’s first meeting of 2021 on Thursday. Representatives from the Biotechnology Innovation Organization (BIO) and Pfizer discussed the vaccine.
Amy Walker, the director of Infectious Diseases Policy at BIO, heralded the process of creating the vaccine over the past 11 months. Since the pandemic began in March, 838 drug development programs launched across the country. Many were focused on finding a COVID-19 vaccine. Their research was largely successful as well, as creating a vaccine in less than a year far outpaces previous vaccination efforts.
The Healthcare Leadership Council issued the following news:
Experts from across healthcare have identified specific policy and regulatory recommendations to improve the nation s ability to prepare for and respond to future health crises. The recommendations are part of a new report released by the
Healthcare Leadership Council and
Duke-Margolis Center for Health Policy and result from collaboration with more than 100 private-sector, nonprofit, and government organizations and stakeholders to assess the response to COVID-19 and the nation s existing disaster preparedness infrastructure.
The recommendations include some temporary steps taken to address the COVID-19 pandemic, which have proven beneficial and should be made permanent going forward, the experts say. These include making it easier for public and private organizations to work in partnership, prioritizing supply chain readiness before crises arise, streamlining regulations that allow providers to practice medicine whe